Rescue of glutaric aciduria type I by GalNAc-conjugated siRNA against aminoadipate semialdehyde synthase
Glutaric aciduria type I (GA-1) is a severe metabolic disorder caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH), leading to accumulation of organic acids in the brain and resulting in striatal injury and progressive movement disorders. Although early diagnosis and dietary management reduce risk, one-third of patients still develop debilitating neurological complications. We previously demonstrated that liver-specific deletion of aminoadipate semialdehyde synthase (AASS), an upstream enzyme in lysine degradation, is a promising therapeutic strategy. Here, we tested an N -acetylgalactosamine (GalNAc)–conjugated siRNA against Aass . Treatment of neonatal Gcdh −/− mice rescued lethality and improved the brain pathology while reducing toxic metabolites in the brain and other organs. Serum biomarkers, including glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine, predicted neurological outcomes, supporting their use for therapeutic monitoring. Although systemic metabolite concentrations declined, their urinary excretion remained elevated, consistent with a renal washout phenomenon and preserved excretory capacity. These findings demonstrate the potential of liver-targeted small interfering RNA (siRNA) therapy as a treatment for GA-1.
Authors
- Cheryl K. Peck (ORCID: https://orcid.org/0009-0007-4018-7403)
- Mercedes Barzi (ORCID: https://orcid.org/0000-0003-3428-2782)
- Karl‐Dimiter Bissig (ORCID: https://orcid.org/0000-0002-9577-9250)
- Timothy C. Wood (ORCID: https://orcid.org/0000-0003-0831-0188)
- Leila J. Noetzli (ORCID: https://orcid.org/0009-0005-0405-502X)
- Ashlee R. Stiles
- James Beasley (ORCID: https://orcid.org/0000-0003-0147-9490)
- Areeg El‐Gharbawy (ORCID: https://orcid.org/0000-0002-0682-388X)
- Beatrice Bissig-Choisat (ORCID: https://orcid.org/0000-0003-4241-5573)
- Sarah P. Young (ORCID: https://orcid.org/0000-0002-7671-016X)
- SABRINA BELOZEROVA (ORCID: https://orcid.org/0009-0005-4347-8893)
- Haoyue Zhang (ORCID: https://orcid.org/0000-0002-8869-4531)
- Maiya Fujiwara (ORCID: https://orcid.org/0009-0004-3070-2959)
- Natasha Murugan (ORCID: https://orcid.org/0009-0000-8285-1367)
- Yunhan Ma (ORCID: https://orcid.org/0009-0009-6821-5351)
Institutions
- Alnylam Pharmaceuticals (United States) (US)
- Duke University (US)
- Children's Hospital Colorado (US)
- Center for Human Genetics (US)
- Duke Medical Center (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Science Translational Medicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1126/scitranslmed.aej2067
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Alnylam Pharmaceuticals
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Child Health and Human Development
- Duke Cancer Institute